Activation of AMPK pathway by low‑dose donafenib and atorvastatin combination improves high‑fat diet‑induced metabolic dysfunction‑associated steatotic liver disease-Reference-Cited by-同舟云学术

Activation of AMPK pathway by low‑dose donafenib and atorvastatin combination improves high‑fat diet‑induced metabolic dysfunction‑associated steatotic liver disease

Published:2024-01-29 Issue:3 Volume:29 Page:
ISSN:1791-2997
Container-title:Molecular Medicine Reports
language:
Short-container-title:Mol Med Rep

Author:

Bai Yaowei¹,Chen Kequan²,Liu Jiacheng¹,Wang Yingliang¹,Wang Chaoyang¹,Ju Shuguang¹,Zhou Chen¹,Yao Wei¹,Xiong Bin³,Zheng Chuansheng¹

Affiliation:

1. Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China

2. Department of Gastroenterology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510120, P.R. China

3. Department of Interventional Radiology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510120, P.R. China

Publisher

Spandidos Publications

Reference50 articles.

1. Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention;Younossi;Nat Rev Gastroenterol Hepatol,2018

2. Phase IIa results for potential NAFLD therapy;Greenhill;Nat Rev Endocrinol,2022

3. A multi-society Delphi consensus statement on new fatty liver disease nomenclature;Rinella;Hepatology,2023

4. Can we use old NAFLD data under the new MASLD definition?;Song;J Hepatol,2023

5. Metabolic dysfunction-associated steatotic liver disease (MASLD) definition is better than MAFLD criteria for lean patients with non-alcoholic fatty liver disease (NAFLD);De;J Hepatol,2023

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Donafenib inhibits PARP1 expression and induces DNA damage, in combination with PARP1 inhibitors promotes apoptosis in liver cancer cells;Anti-Cancer Drugs;2024-06-26